Apixaban a reasonable alternative to warfarin in patients with severe renal impairment
December 9, 2021
Is apixaban a safe alternative to warfarin in patients with severe renal impairment?
Timing of initiation of renal-replacement therapy in acute kidney injury
December 8, 2021
In critically ill patients, does early renal-replacement therapy (RRT), compared with standard therapy, improve death from any cause at 90 days?
Comparing the efficacy and safety of common SIADH treatments
November 24, 2021
Is fluid restriction or the addition of furosemide with or without NaCl supplementation more efficacious for the treatment of hyponatremia caused by syndrome of inappropriate antidiuretic hormone (SIADH)?
What makes a urinary tract infection complicated?
November 22, 2021
There are multiple interpretations of complicated UTIs.
Timing of renal-replacement therapy for AKI in the ICU
November 19, 2021
Does earlier initiation of renal-replacement therapy (RRT) improve mortality in the ICU?
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
November 19, 2021
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
Fluoroquinolones linked to sudden death risk for those on hemodialysis
October 25, 2021
Most patients undergoing hemodialysis have a least one risk factor for drug-induced QT interval prolongation.
ACE-I or ARB therapy in patients with low eGFR
August 26, 2021
Is it safe to continue angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) therapy in patients whose estimated glomerular filtration rate (eGFR) has decreased to below 30 mL/min per 1.73 m2?
U.S. kidney transplants grow in number and success
August 24, 2021
Data from 1996 to 2019 show more U.S. kidney transplants recently than ever before, and steady improvements in graft and patient survival.
SGLT2 inhibitor use rising in patients with DKD
August 23, 2021
Use of SGLT2 inhibitors in patients with type 2 diabetes rose sharply in 2019 and early 2020. GLP-1 RA use also showed recent gains.